Poseida Therapeutics Inc (PSTX) News

Form SC14D9C - Written communication relating to third party tender offer

Form SC14D9C - Written communication relating to third party tender offer

Form 8-K - Current report

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. PR Newswire SAN DIEGO...

Form 8-K - Current report

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical...

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Poseida Therapeutics to Present at Two Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 11, 2024 SAN...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 PR Newswire SAN...

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell...

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche PR...

MaxCyte Appoints Cynthia Collins to its Board of Directors

ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...